Tumor Immune Microenvironment Clusters in Localized Prostate Adenocarcinoma: Prognostic Impact of Macrophage Enriched/Plasma Cell Non-Enriched Subtypes

• Published in: Journal of clinical medicine 2020-06, Vol.9 (6), p.1973
• Main Authors: Jairath, Neil K, Farha, Mark W, Srinivasan, Sudharsan, Jairath, Ruple, Green, Michael D, Dess, Robert T, Jackson, William C, Weiner, Adam B, Schaeffer, Edward M, Zhao, Shuang G, Feng, Felix Y, El Naqa, Issam, Spratt, Daniel E
• Format: Article
• Language: English
• Subjects: Antigens; Cancer therapies; Clinical medicine; Datasets; Gene expression; Immune system; Medical prognosis; Metastasis; Patients; Plasma; Prostate cancer; Radiation therapy; Survival analysis; Tumors
• ISSN: 2077-0383; 2077-0383
• DOI: 10.3390/jcm9061973

Prostate cancer (PCa) is characterized by significant heterogeneity in its molecular, genomic, and immunologic characteristics. Whole transcriptome RNAseq data from The Cancer Genome Atlas of prostate adenocarcinomas ( = 492) was utilized. The immune microenvironment was characterized using the CIBERSORTX tool to identify immune cell type composition. Unsupervised hierarchical clustering was performed based on immune cell type content. Analyses of progression-free survival (PFS), distant metastases, and overall survival (OS) were performed using Kaplan-Meier estimates and Cox regression multivariable analyses. Four immune clusters were identified, largely defined by plasma cell, CD4 Memory Resting T Cells (CD4 MR), and M0 and M2 macrophage content (CD4 MR Plasma Cell M0 M2 , CD4 MR Plasma Cell M0 M2 , CD4 MR Plasma Cell M0 M2 , and CD4 MR Plasma Cell M0 M2 ). The two macrophage-enriched/plasma cell non-enriched clusters (3 and 4) demonstrated worse PFS (HR 2.24, 95% CI 1.46-3.45, = 0.0002) than the clusters 1 and 2. No metastatic events occurred in the plasma cell enriched, non-macrophage-enriched clusters. Comparing clusters 3 vs. 4, in patients treated by surgery alone, cluster 3 had zero progression events ( < 0.0001). However, cluster 3 patients had worse outcomes after post-operative radiotherapy ( = 0.018). Distinct tumor immune clusters with a macrophage-enriched, plasma cell non-enriched phenotype and reduced plasma cell enrichment independently characterize an aggressive phenotype in localized prostate cancer that may differentially respond to treatment.